The outcome of HSCT and the risk for GvHD is not only dependent on genetic matching but is strongly influenced by the type and number of donor-derived immunological cells in the HSCT graft.
We can assume that the cellular content and proportions of different cell types in the HSCT graft are important in safe and efficient HSCT, as is also the spectrum of cytokines the cells secrete. However, there are no systematic studies on the immunological content of clinical HSCT grafts. In current HSCT protocols, the cell and cytokine profile of the graft is not characterized.
In the project we systematically characterise the immune cell profiles of clinical HSCT grafts and study their associations with the outcome of HSCT.
From all grafts we estimate the numbers of the following cell populations
In addition, some other subpopulations are studied.
The results indicate that there are, e.g.
- considerable variation between individual HSCT grafts in their cell contents;
- HSCT grafts from bone marrow differ from that from peripheral blood;
- levels of certain cell populations are associated with the outcome of HSCT
The study is done in collaboration with Turku University Hospital.